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Abstract: Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death 
throughout the world and is largely associated with cigarette smoking. Despite the appreciation 
of the central role of smoking in the development of COPD, only a relatively small number of 
smokers (15%–20%) develop COPD. Recent studies depicting familial aggregation suggest 
that some subjects may have a genetic predisposition to developing COPD. In this respect, a 
number of single nucleotide polymorphisms have been reported in association with different 
COPD features (subphenotypes), although much of this data remains controversial. Classical 
genetic studies (including twin and family studies) assume an “equal-environment” scenario, 
but as gene-environment interactions occur in COPD, this assumption needs revision. Thus, new 
integrated models are needed to examine the major environmental factors associated with COPD 
which include smoking as well as air pollution, and respiratory infections, and not only genetic 
predisposition. Revisiting this area, may help answer the question of what has more bearing in 
the pathogenesis of COPD—the environment or the genomic sequence of the affected subjects. 
It is anticipated that an improved understanding of this interaction will both enable improved 
identiﬁ  cation of individuals susceptible to developing this disease, as well as improved future 
treatments for this disease.
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Introduction
The development of COPD is most likely a series of complex interactions between 
noxious airborne agents together with a genetic predisposition. Exposure to cigarette 
smoke and air pollution as well exposure to infectious agents are commonly associ-
ated with the development of COPD (Anthonisen et al 2005). Because COPD does 
not develop in all smokers, genetic predisposition such as protease-antiprotease 
imbalance is a plausible explanation for the development of airways inﬂ  ammation 
and airﬂ  ow obstruction (Molﬁ  no 2004a). Conversely, it is also possible that lungs 
adapt to environmental toxins, so that COPD usually does not develop in the major-
ity of smokers (Molﬁ  no 2004b). While cigarette smoking is the major environmental 
factor associated with the development of COPD, some subjects continue to show 
decline in lung function after sustained smoking cessation. This suggests the presence 
or airways remodeling which persists and varies among subjects due to differences 
in the genetic architecture (Makris et al 2007; Pinho et al 2007). In addition, the role 
of air pollution and infections in the development and persistence of COPD even 
after sustained smoking cessation remain unclear, but their roles in provoking acute 
exacerbations are well established (Donaldson et al 2002; Lipton et al 2005; Naess 
et al 2007; Ko et al 2007).
Figure 1 shows a simpliﬁ  ed, classical, theoretical model of how genes and the 
environment may interact to induce and maintain the COPD phenotype. While these 
gene-environmental interactions are at present poorly understood, there may be a International Journal of COPD 2008:3(3) 492
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delicate balance between environmental stimuli and genes. 
In one extreme, such as that represented by PiZZ phenotype 
or indeed by severe smoking, either genetic predisposition or 
environmental factors may be sufﬁ  cient to provoke COPD. 
It is more likely, however that in the COPD patient, the 
phenotype is under the inﬂ  uence of complex gene-gene and 
gene-environment interactions, as well as epigenetic modi-
ﬁ  cations providing additional complexity to deﬁ  ne a single 
etiopathogenic factor (Molﬁ  no 2007a). In this regard, although 
α1-antitrypsin deﬁ  ciency results in COPD, it can also cause a 
variable phenotype because of the inﬂ  uence of environmen-
tal factors such as smoking (De Meo et al 2007). Moreover, 
although familial aggregation in COPD has been described, 
most of the studies have assumed an “equal-environment” 
model and while associations of single nucleotide polymor-
phisms (SNPs) with COPD phenotypes have been described, 
most remain controversial and unsubstantiated in other studies 
(Cookson 2006). Finally, it is also important to note that the 
inﬂ  uence of both gender as well as history of bronchial asthma 
may also contribute towards the COPD phenotype and are 
themselves subject to gene-gene interactions (Silverman et al 
2000; Molﬁ  no 2007a).
Gene-environment interactions
Gene-environment interactions in COPD are suggested by 
the results of several studies. For example, in patients with 
the PiZZ phenotype who have low levels of circulating 
α1-antitrypsin (Stoller et al 2005), smoking is the single most 
important factor associated with a reduction in forced expira-
tory volume in 1 second (FEV1). Other factors associated with 
reduced FEV1 values in such phenotype include male gender, 
a diagnosis of asthma before age 16 years, and symptoms of 
asthma or chronic bronchitis (De Meo et al 2007). In subjects 
with less severe reduction of α1-antitrypsin, it is unclear 
whether the intermediate blood levels of α1-antitrypsin are 
sufﬁ  cient to avert lung function decline, even if the individuals 
are exposed to noxious or toxic environments. In one study, 
lung function did not decline in subjects with less severe 
phenotypes (eg, PiMM, PiMS, or PiMZ), even if smokers 
were included in the analysis (Silva et al 2003). This ﬁ  nd-
ing contradicts previous reports in the literature (Dahl et al 
2002). One possible explanation is that the PiMZ phenotype 
requires the presence of family history of COPD to exhibit 
a faster decline in FEV1. This suggests that other gene-gene 
interactions may be needed, in order to see a signiﬁ  cant gene-
environment interaction (Molﬁ  no 2007a).
Cigarette smoking and air pollution both affect the lung 
compartment, and their effects may be modulated by genes 
(perhaps even the whole genome sequence!) of exposed 
individuals (Conrad and Antonarakis 2007; Kehrer-Sawatzki 
2007; Stranger et al 2007). In COPD, smoking cessation has 
been shown to be the only non-pharmacological intervention 
to slow the decline in FEV1. In this respect, the Lung Health 
Study studied 5,887 patients with mild to moderate COPD 
for 5 years and results of a 14-year follow-up were reported 
in 2005. Patients with sustained smoking cessation showed a 
signiﬁ  cant increase in FEV1 during the ﬁ  rst year after smoking 
cessation, followed by a steady decline thereafter. Patients 
with intermittent smoking cessation had a rate of decline in 
FEV1 between those with sustained cessation and those who 
continued to smoke. This shows how a major environmental 
change—apparently regardless of genetic architecture—can 
affect the initial progression of COPD (Anthonisen et al 
2005). It may be that genes inﬂ  uence the continuous reduc-
tion in FEV1 in patients with sustained smoking cessation, 
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Figure 1 Interaction of environment and genes in chronic obstructive pulmonary disease (COPD).International Journal of COPD 2008:3(3) 493
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COPD can also develop in nonsmokers. Behrendt (2005) 
examined approximately 14000 subjects, of whom ∼7500 
were nonsmokers. In this group, 4.7% had mild COPD 
(80% were women) and 1.9% had moderate-to-severe 
COPD (80% men). Previous physician-diagnosed asthma 
and age were risk factors, whereas urban residence, occupa-
tion, and allergies were not. The study had several limitations 
since many factors were not collected or reported. These 
included gestational age, birth weight, lower respiratory tract 
infections in childhood, parental smoking during gestation 
and childhood, exposure to environmental tobacco smoke 
and other airway irritants throughout adulthood, and family 
history of COPD (Behrendt 2005).
Air pollution is another major environmental factor 
per se involved in the development of COPD (Lipton et al 
2005; Ko et al 2007; Naess et al 2007). Major outdoor 
pollutants include nitrogen dioxide (NO2), sulfur dioxide, 
ozone, and particulate matter (diesel exhaust). The major 
source of NO2 pollution is road trafﬁ  c, and the highest 
concentrations are evident during the morning and evening 
rush hours. At a global level, the mean tropospheric NO2 
corresponds to areas of major industrialization. Conversely, 
indoor pollution is a signiﬁ  cant problem in sub-Saharan 
Africa (SSA), where it is caused by household energy use 
of biomass fuel, such as wood, charcoal, dung, and agri-
cultural residues (Figure 2). Biomass burning alone causes 
∼400,000 annual deaths in SSA, both from respiratory 
infections in children and COPD in nonsmoking women 
(Bailis et al 2005).
Once COPD is established, infections are the single best-
characterized factor associated with acute exacerbations of 
COPD. The inﬂ  uence of infections in the development and 
persistence of COPD remains less clear. Patients with frequent 
exacerbations of COPD show a faster decline of FEV1 than 
patients with less frequent exacerbations even when smoking 
status is taken into consideration (Donaldson 2002). Interest-
ingly, it has recently been reported that patients with frequent 
exacerbations of COPD have different genotypes in a particu-
lar allelic variant leading to a lack of the leukocyte chemotactic 
factor CCL1 (also known as i-309) which was associated with 
infection in some patients (Takabatake et al 2006).
Models to study gene-environment 
interactions
The hypothesis that subjects who develop COPD have 
genetic susceptibility to high-risk environments requires 
substantiation through an integrative model. The two 
most frequently used approaches in conditions in which 
gene-environment interactions are suspected include the 
“bottom-up” and “top-down” methods.
In the “bottom-up” approach, individual genetic and 
environmental factors are identiﬁ  ed. The limitations of this 
approach are the difﬁ  culties in establishing statistical validity 
and in quantifying the gene-gene and gene-environment inter-
actions. The “top-down” approach considers the risks at the 
population level, using twin and family association studies, as 
well as data on environmental factors in determining the trait. 
The major limitation of this approach is the impact of multiple 
Figure 2 Global mean tropospheric nitrogen dioxide (NO2) vertical column density between January 2003 and June 2004. Concentrations increase with color intensity: blue, 
lowest NO2 concentrations; deep red, highest NO2 concentrations. Eighteen-month average taken from www.esa.int/images/pollution_global_L.International Journal of COPD 2008:3(3) 494
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genetic variants, as well as the whole genome sequence of 
each individual, on disease susceptibility, which leads to an 
increasingly intractable algebra (Wallace 2006).
In the “bottom-up” approach, genetic susceptibility 
studies have demonstrated that in addition to familial aggre-
gation, TNF-α and IL-13 promoter polymorphisms, as well 
as TIMP-2 polymorphisms, are signiﬁ  cantly associated 
with the presence of smoking-related COPD, whereas SNPs 
in MMP1 and MMP12, in the anti-oxidant genes GSTM1, 
GSTT1, GSTP1, HMOX-1, and mEPHX are associated with 
an accelerated decline of lung function in COPD (Molﬁ  no 
2004a, 2004b, 2007a). More recently, SNPs have also been 
reported in relatives of patients with COPD, or associated 
with lung hyperinﬂ  ation or other sub phenotypes (eg, signs, 
symptoms, or exercise tests in COPD).
Few of these results have been reproduced in other studies 
(Molﬁ  no 2007a). One potential explanation maybe the low 
frequency of SNPs with an occurrence of approximately one 
SNP in 300–500 base pairs in the human genome, it is pos-
sible that some of the associations were random. Therefore, 
a P value 0.005 and some plausible pathophysiological 
mechanism by which the SNP is relevant in COPD are highly 
desirable (Cookson 2006). Furthermore, in the “bottom-
up” approach, rather than searching for direct main-effect 
associations between candidate genes and COPD, other 
experimental designs may identify how the genotype can 
moderate the response of a subject to environmental stimuli. 
In this regard, subjects carrying a variable number of tandem 
repeat polymorphisms in the D4 dopamine receptor gene 
experienced a craving signiﬁ  cantly more often when in the 
presence of another smoker (Hutchinson et al 2002). Results 
of psychiatry studies will add complexity to the possible 
gene-environment interaction in COPD, since addiction is 
the main cause of cigarette smoking.
New approaches such as genome-wide association studies 
(GWAS) may be able to pinpoint genetic loci associated with 
COPD or its subphenotypes (Silverman 2006) This approach 
can be robust if one assumes the presence of non-confounder 
factors and no interaction with the environment. Advantages 
include reduced costs, since GWAS often follow a staged 
design, in which a proportion of samples are genotyped ﬁ  rst 
and a proportion of the most promising markers are geno-
typed later in the remaining samples (Ye et al 2005). The 
standard approach is to focus on ﬁ  ndings that are statistically 
signiﬁ  cant when stage 2 data are analyzed; an alternative 
method is to analyze the results from different stages jointly 
(Skol et al 2007). In GWAS, the associations of the genome 
information (eg, SNPs) among different subjects, and the 
associations between different genetic loci and the pheno-
type (eg, FEV1 decline) can be expressed using probability 
functions. Based on these functions, reliable conclusions can 
be obtained about the associations between phenotype and 
genes using SNPs—called tagging SNPs (Molﬁ  no 2007a). 
Some limitations of GWAS include: the phenotype must be 
well characterized to enable selection of patients likely to 
share the genetic cause of COPD; thousands of patients and 
control subjects are needed to ensure the statistical reliability 
of the study; and bioinformatics challenges remain regarding 
identiﬁ  cation of true positives. Another potential limitation 
involves the possibility of missing particular mutations in 
COPD, which may not be tagged by a speciﬁ  c SNP (Molﬁ  no 
2007a). Moreover, the sequence of the human genome con-
tinues to uncover other forms of genetic variation (apparently 
normal) such as copy-number variation. Copy-number varia-
tions are frequent and inheritable, and include the deletion 
or duplication of DNA in 1 gene and the presence of 2 
copy-number variations. They may inﬂ  uence susceptibility 
to the environment because they can change gene dose and 
expression (Conrad and Antonarakis 2007; Kehrer-Sawatzki 
2007; Stranger et al 2007). Unless COPD is produced by 
a single gene disorder, it is possible that GWAS in COPD 
will only reveal genes that are associated with minimal or 
moderate susceptibility, as is the case with the already known 
environmental factors (Wallace 2006).
Since the development of COPD appears to require that a 
highly predisposed individual be present in a high-risk envi-
ronment, a 4-category model may also be useful as a starting 
point for “top-down” analysis (Figure 3) (Molﬁ  no 2007b). 
This model, developed by Khoury and Wagener (1995), aban-
dons the classical assumptions of twins studies, as well as the 
Fisher (1918) assumption, which suggests that genes are risk 
factors for common traits in a manner dominated by an addi-
tive polygenic term. This model has been adapted and shown 
that there may be limited potential for reducing the incidence 
of common diseases, such as COPD, through environmental 
interventions targeted by genotype (Wallace 2006).
It appears that the individual genotype that determines 
the susceptibility to complex disease tends to be exaggerated 
by the classical models due to the assumption of “equal 
environment” in twin studies or no gene-environment inter-
actions at all. The model proposed by Wallace reveals that 
inherited genetic variants may be important in determining 
susceptibility only for the relatively rare familial forms of dis-
ease (Wallace 2006). Thus, the studies of familial aggregation 
may be incorrect, and the search for additional susceptibility 
genes may turn out to be largely fruitless.International Journal of COPD 2008:3(3) 495
Gene-environment interactions in COPD
It appears that there is a need to revise our assumptions on 
how COPD develops (Caspi and Mofﬁ  tt 2006; Molﬁ  no 2007b) 
(Figure 4). The gene-to-COPD approach assumes direct linear 
relations between genes and COPD (eg, PiZZ with severe 
phenotype). This model has been used to study a number of 
COPD phenotypes (eg, in broader COPD populations than 
the PiZZ homozygous). Subphenotypes are thought to have 
simpler genetic underpinnings than COPD itself. Thus, this 
assumption pursues the hypothesis that it will be easier to iden-
tify genes associated with subphenotypes than with the whole 
constellation of COPD signs and symptoms. This approach 
adds an intermediate measure to the ﬁ  nal diagnosis of COPD 
(eg, the BODE index: body mass index, FEV1, dyspnea, and 
exercise capacity index; Figure 4) (Celli et al 2004).
A third approach (Figure 4) seeks to incorporate informa-
tion about the environment (eg, pollutants). This approach of 










Figure 3 Four-category model of gene-environment interaction in chronic obstructive pulmonary disease (COPD).
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Figure 4 Assumptions in models of gene-environment interactions in chronic obstructive pulmonary disease (COPD). BODE, multidimensional index including body mass 
index, airﬂ  ow obstruction, dyspnea, and exercise capacity index. Adapted from Caspi and Mofﬁ  tt (2006).International Journal of COPD 2008:3(3) 496
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environment-gene interaction differs fundamentally from the 
“main-effects” approach, which assumes that genes cause 
COPD, an approach used in single-gene diseases (Fisher 
1918). The environment-gene approach assumes that the envi-
ronment causes the disorder and that genes cause the suscep-
tibility to pathogens (eg, women and children in SSA). There 
is no expectation of an association between gene and COPD 
in this model in the absence of environmental pollutants or 
pathogens. The environment-gene approach in COPD is based 
on the fact that COPD is due to a major environmental cause 
and that subjects show a heterogeneous response to that cause. 
The fourth approach is more complex because it includes an 
additional co-morbidity such as nicotine addiction (Caspi and 
Mofﬁ  t 2006). Therefore, it may be applicable to the majority 
of patients with COPD in the industrialized world.
Molecular mechanisms
in gene-environment interactions
We are just beginning to understand how the environment 
can interact with the genome. The genetic response to the 
environment can be in the form of large-scale recombination, 
chromosomal breakage-fusion-bridge cycles, and loss of chro-
mosomes or chromosome fragments. Such changes may be 
induced or facilitated by transposition of DNA (Madlung and 
Comai 2004). In addition, chemical modiﬁ  cations of histones, 
around which DNA is coiled and coincide with modiﬁ  cations 
in transcriptional activity, can be inherited. The modiﬁ  cations 
that alter DNA activity without altering its basic nucleotide 
structure are referred to as epigenetic changes and include 
the chemical modiﬁ  cations of DNA or histones, usually with 
methyl or acetyl groups, which have the potential to change 
gene expression and bring the phenotype into being (Wolffe 
and Matzke 1999). Methylation of DNA functions as gene 
silencing, and is vital to the maintenance of proper cell division. 
Acetylation of histones leads to gene activity, and gene expres-
sion is controlled by packing and unpacking DNA from inac-
cessible to accessible nucleosomes. Packing and unpacking 
is achieved by acetylation and deacetylation of the histones 
of the nucleosome core (Segal 2006). In COPD, it has been 
shown that deacetylation is needed to repress the expression of 
pro-inﬂ  ammatory cytokines (which is accompanied by hyper-
acetylation) (Barnes et al 2005) and to enable the response to 
corticosteroids (Barnes 2006) It is possible that other molecular 
mechanisms exist and remain to be uncovered.
Conclusions
Chronic obstructive pulmonary disease is a complex 
condition mainly associated with cigarette smoking, as 
well as exposure to air pollution and respiratory pathogens. 
It is evident that only a relatively small number of exposed 
individuals develop COPD, and a fraction suffer exacerba-
tions when exposed to noxious agents or pathogens. The 
classical approach to understanding the pathogenesis of 
the disease is to accept that different genetic loci determine 
the phenotype in COPD and to continue the search for such 
predisposing loci.
Models of gene-environment interaction suggest that either 
it may be difﬁ  cult to identify predisposing loci or, if identiﬁ  ed, 
they will be found to have minimal effects on the development 
of COPD. Thus, new approaches to the study of COPD are 
needed. It may be appropriate to avoid the equal-environment 
assumption and to consider haplotype or even whole genome 
sequences to determine susceptibility to COPD.
Future study designs should characterize the phenotype 
and history of potential exposures of study subjects. The 
latter category should include stratiﬁ  cation of the intensity 
of smoking, determination of pollutants, type of respiratory 
infections not only during the subject’s recent adult years, 
but also during childhood, and occupational exposures.
Disclosure
Dr Molfino and Coyle are employees of MedImmune, 
Gaithersburg, MD. Presented in part at the 2007 European 
Society of Clinical Investigation Scientific meeting in 
Uppsala, Sweden.
References
Anthonisen NR, Skeans MA, Wise RA, et al. 2005. The effects of a smoking 
cessation intervention on 14.5-year mortality: a randomized clinical 
trial. Ann Intern Med, 142:233–9.
Bailis R, Ezzati M, Kammen DM. 2005. Mortality and greenhouse gas 
impacts of biomass and petroleum energy futures in Africa. Science, 
308:98–103.
Barnes PJ, Adcock IM, Ito K. 2005. Histone acetylation and deacetylation: 
importance in inﬂ  ammatory lung diseases. Eur Respir J, 25:552–63.
Barnes PJ. 2006. How corticosteroids control inﬂ  ammation: Quintiles Prize 
Lecture 2005. Br J Pharmacol, 148:245–54.
Behrendt CE. 2005. Mild and moderate-to-severe COPD in nonsmokers: 
distinct demographic proﬁ  les. Chest, 128:1239–44.
Caspi A, Mofﬁ  tt TE. 2006. Gene-environment interactions in psychiatry: 
joining forces with neuroscience. Nat Rev Neurosci, 7:583–90.
Celli BR, Cote CG, Marin JM, et al. 2004. The body-mass index, airﬂ  ow 
obstruction, dyspnea, and exercise capacity index in chronic obstructive 
pulmonary disease. N Engl J Med, 350:1005–12.
Conrad B, Antonarakis SE. 2007. Gene duplication: a drive for phenotypic 
diversity and cause of human disease. Annu Rev Genomics Hum Genet, 
8:17–35.
Cookson WO. 2006. State of the art. Genetics and genomics of chronic 
obstructive pulmonary disease. Proc Am Thorac Soc, 3:473–5.
Dahl M, Tybjaerg-Hansen A, Lange P, et al. 2002. Change in lung function 
and morbidity from chronic obstructive pulmonary disease in alpha1-
antitrypsin MZ heterozygotes: A longitudinal study of the general 
population. Ann Intern Med, 136:270–9.International Journal of COPD 2008:3(3) 497
Gene-environment interactions in COPD
DeMeo DL, Sandhaus RA, Barker AF, et al. 2007. Determinants of air-
ﬂ  ow obstruction in severe alpha 1-antitrypsin deﬁ  ciency. Thorax, 
62:806–13.
Donaldson GC, Seemungal TA, Bhowmik A, et al. 2002. Relationship 
between exacerbation frequency and lung function decline in chronic 
obstructive pulmonary disease. Thorax, 57:847–52.
Fisher RA. 1918. The correlation between relatives on the supposition of 
Mendelian inheritance. Philosophical Transactions of the Royal Society 
of Edinburgh, 52:399–433.
Hutchinson KE, La Chance H, Naiura R, et al. 2002. The DRD4 VNTR 
polymorphism inﬂ  uences reactivity to smoking cues. J Abnorm Psychol, 
111:134–43.
Kehrer-Sawatzki H. 2007. What a difference copy number variation makes. 
Bioessays, 29:311–13.
Khoury MJ, Wagener DK. 1995. Epidemiological evaluation of the use of 
genetics to improve the predictive value of disease risk factors. Am J 
Hum Genet, 56:835–44.
Ko FW, Tam WW, Chan DP, et al. 2007. The temporal relationship between 
air pollutants and hospital admissions for chronic obstructive pulmonary 
disease in Hong Kong. Thorax, 62:780–5.
Lipton R, Banerjee A, Dowling KC, et al. 2005. The geography of COPD 
hospitalization in California. COPD, 2:435–44.
Madlung A, Comai L. 2004. The effect of stress on genome regulation and 
structure. Ann Bot (Lond), 94:481–95.
Makris D, Moschandreas J, Damianaki A, et al. 2007. Exacerbations and 
lung function decline in COPD: New insights in current and ex-smokers. 
Respir Med, 101:1305–12.
Molﬁ  no NA. 2004a. Genetics of COPD. Chest, 125:1929–40.
Molﬁ  no NA. 2004b. Lung function evolution and respiratory symptoms. 
Arch Bronconeumol, 40:429–30.
Molﬁ  no NA. 2007a. Current thinking on genetics of chronic obstructive 
pulmonary disease. Curr Opin Pulm Med, 13:107–13.
Molﬁ  no NA. 2007b. COPD: what is genes and what is environment? Eur 
J Clin Inv, 37:37.
Naess O, Nafstad P, Aamodt G, et al. 2007. Relation between concentration 
of air pollution and cause-speciﬁ  c mortality: four-year exposures to 
nitrogen dioxide and particulate matter pollutants in 470 neighborhoods 
in Oslo, Norway. Am J Epidemiol, 165:435–43.
Pinho RA, Chiesa D, Mezzomo KM, et al. 2007. Oxidative stress in chronic 
obstructive pulmonary disease patients submitted to a rehabilitation 
program. Respir Med, 101:1830–5.
Segal E, Fondufe-Mittendorf Y, Chen L, et al. 2006. A genomic code for 
nucleosome positioning. Nature, 442:772–8.
Silva GE, Sherrill DL, Guerra S, et al. 2003. A longitudinal study of alpha1-
antitrypsin phenotypes and decline in FEV1 in a community population. 
Chest, 123:1435–40.
Silverman EK, Weiss ST, Drazen JM, et al. 2000. Gender-related differ-
ences in severe, early-onset chronic obstructive pulmonary disease. Am 
J Respir Crit Care Med, 162:2152–8.
Silverman EK. 2006. Progress in chronic obstructive pulmonary disease 
genetics. Proc Am Thorac Soc, 3:405–8.
Skol AD, Scott LJ, Abecasis GR, et al. 2006. Joint analysis is more efﬁ  cient 
than replication-based analysis for two-stage genome-wide association 
studies. Nat Genet, 38:209–13.
Stoller JK, Snider GL, Brantly ML, et al. 2005. American Thoracic Society/
European Respiratory Society Statement: Standards for the diagnosis 
and management of individuals with alpha-1 antitrypsin deﬁ  ciency. 
Pneumologie, 59:36–68.
Stranger BE, Forrest MS, Dunning M, et al. 2007. Relative impact of 
nucleotide and copy number variation on gene expression phenotypes. 
Science, 315:848–53.
Takabatake N, Shibata Y, Abe S, et al. 2006. A single nucleotide polymor-
phism in the CCL1 gene predicts acute exacerbations in chronic obstruc-
tive pulmonary disease. Am J Respir Crit Care Med, 174:875–85.
Wallace HM. 2006. A model of gene-gene and gene-environment interac-
tions and its implications for targeting environmental interventions by 
genotype. Theor Biol Med Model, 3:35.
Wolffe AP, Matzke MA. 1999. Epigenetics: regulation through repression. 
Science, 286:481–6.
Ye Y, Zhong X, Zhang H. 2005. A genome-wide tree- and forest-based 
association analysis of comorbidity of alcoholism and smoking. BMC 
Genet, 6(suppl 1):S135.